Effect of Denosumab in Erosion Healing in RA

• Status: Completed
• Trial end date: 2020-05-24
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the effects of denosumab on erosion healing and change in physical function in RA patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese University of Hong Kong
• Treatments: Denosumab

Criteria

Inclusion Criteria:

• ≥18 years old

• DAS28 ≤5.1

• without severe deformity in MCP joints which would influence the longitudinal assessment of HR-pQCT

Exclusion Criteria:

• RA functional status class IV (limited in ability to perform usual self-care, vocational, and avocational activities)

• treatment with any biologic DMARDs for RA treatment within 8 weeks before randomisation

• pregnancy or premenopausal women planning pregnancy

• previous use of denosumab, zoledronic acid or teriparatide

• Hyperparathyroidism

• contraindications to denosumab

• Bisphosphonate, biologic DMARDs and the use of oral glucocorticoid >10 mg/day (prednisolone equivalent)